May 25, 2022 5:00 pm EDT Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting
May 24, 2022 5:00 pm EDT TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
May 20, 2022 7:00 am EDT Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer
May 19, 2022 7:00 am EDT Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC
May 10, 2022 7:00 am EDT Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings
May 6, 2022 7:00 am EDT Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety
May 3, 2022 5:00 pm EDT Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives
Apr 29, 2022 7:00 am EDT Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests
Apr 27, 2022 7:00 am EDT Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for TissueCypher® Barrett’s Esophagus Test and Ability to Identify Patients at High Risk of Progressing to Esophageal Cancer
